Next Century Growth Investors Llc Lowered Position in Axogen Inc (NASDAQ:AXGN) by $11.31 Million as Price Rose

May 17, 2018 - By Margaret Guttierez

AxoGen, Inc. (NASDAQ:AXGN) Corporate Logo

Next Century Growth Investors Llc’s holdings in Axogen Inc (NASDAQ:AXGN) is decreased by 47.07% based on its latest 2018Q1 regulatory filing with the SEC. The company’s stock rose 43.24% while stock markets declined as Next Century Growth Investors Llc sold 314,239 shares. At the end of 2018Q1, the 353,403 shares of the health care company held by the institutional investor were valued at $12.90M, down from 667,642 at the end of the previous reported quarter. For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

Next Century Growth Investors Llc is a Minnesota-based institutional investor with more than $3.86 billion AUM in March, 2014. Taken from Next Century Growth Investors latest Adv, the fund reported to have 10 full and part-time employees. Among which 6 performing investment advisory and research functions. The institutional investor had between 26-100 clients.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Total analysts of 7 have positions in AxoGen (NASDAQ:AXGN) as follows: 7 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 21, 2017 according to StockzIntelligence Inc AxoGen has 11 analyst reports. The stock rating was maintained by JMP Securities with “Market Outperform” on Tuesday, May 1. On Friday, March 2 the firm has “Buy” rating given by Lake Street. The stock rating was maintained by Leerink Swann with “Outperform” on Tuesday, November 21. The company rating was maintained by Wedbush on Tuesday, November 21. The stock rating was maintained by Cantor Fitzgerald with “Overweight” on Tuesday, May 1. On Wednesday, February 28 the stock of AxoGen, Inc. (NASDAQ:AXGN) earned “Buy” rating by Cantor Fitzgerald. On Thursday, March 1 the firm has “Market Outperform” rating given by JMP Securities. On Monday, January 8 the stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given by Cantor Fitzgerald.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries.The firm is valued at $1.66 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.Currently it has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: